Signi fi cant ef fi cacies of neoadjuvant and adjuvant chemotherapy for nasopharyngeal carcinoma by meta-analysis of published literature-based randomized , controlled trials

concurrent-adjuvant chemotherapy versus radiotherapy alone for regionally advanced nasopharyngeal carcinoma. J Natl Cancer Inst 2010; 102: 1188–1198. 9. Hill EJ, Nicolay NH, Middleton MR et al. Oxaliplatin as a radiosensitiser for upper and lower gastrointestinal tract malignancies: what have we learned from a decade of translational research? Crit Rev Oncol Hematol. 2012; 83: 353–387. 10. Ma BB, Hui EP, Wong SC et al. Multicenter phase II study of gemcitabine and oxaliplatin in advanced nasopharyngeal carcinoma—correlation with ERCC-1 polymorphisms. Ann Oncol 2009; 20: 1854–1859. 11. Zhang L, Zhao C, Peng PJ et al. Phase III study comparing standard radiotherapy with or without weekly oxaliplatin in treatment of locoregionally advanced nasopharyngeal carcinoma: preliminary results. J Clin Oncol 2005; 23: 8461–8468. 12. Fleming ID, Cooper JS, Henson DE. AJCC Cancer Staging Manual. Philadelphia, PA: Lippincott-Raven 1997. 13. Sanguineti G, Bossi P, Pou A et al. Timing of chemoradiotherapy and patient selection for locally advanced nasopharyngeal carcinoma. Clin Oncol 2003; 15: 451–460. 14. Hui EP, Ma BB, Leung SF et al. Randomized phase II trial of concurrent cisplatinradiotherapy with or without neoadjuvant docetaxel and cisplatin in advanced nasopharyngeal carcinoma. J Clin Oncol 2009; 27: 242–249. 15. Lin JC, Liang WM, Jan JS et al. Another way to estimate outcome of advanced nasopharyngeal carcinoma—is concurrent chemoradiotherapy adequate? Int J Radiat Oncol Biol Phys 2004; 60: 156–164. 16. Zhang AM, Fan Y, Wang XX et al. Increased treatment-related mortality with additional cisplatin-based chemotherapy in patients with nasopharyngeal carcinoma treated with standard radiotherapy. Radiother Oncol 2012; 104: 279–285. 17. Dechaphunkul T, Pruegsanusak K, Sangthawan D et al. Concurrent chemoradiotherapy with carboplatin followed by carboplatin and 5-fluorouracil in locally advanced nasopharyngeal carcinoma. Head Neck Oncol 2011; 3: 30. 18. Chen CY, Lu TX, Zhao C et al. Weekly paclitaxel with concurrent intensitymodulated radiotherapy for nasopharyngeal carcinoma: outcomes of a tolerance trial. Chin J Cancer 2007; 26: 398–402. 19. Lai SZ, Li WF, Chen L et al. How does intensity-modulated radiotherapy versus conventional two-dimensional radiotherapy influence the treatment results in nasopharyngeal carcinoma patients?. Int J Radiat Oncol Biol Phys 2011; 80: 661–668.